Preliminary studies have shown that riluzole, a Na+ channel blocker with antiglutamatergic activity, has neuroprotective efficacy in several models of acute dopaminergic neurodegeneration. A chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) monkey model which comes closer to the slow evolution of Parkinson's disease has recently been developed in order to allow dynamic studies. The present results show that riluzole delayed the appearance of parkinsonian motor abnormalities in this dynamic model, using from 10.2 +/- 1.6 daily injections for the MPTP-treated monkeys (n = 4) to 16.5 +/- 2.0 daily injections for the MPTP + riluzole-treated monkeys (n = 4). These results strongly suggest that riluzole may be beneficial to slow down the rate of progression of Parkinson's disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0014-2999(98)00537-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: People living with ALS (plwALS) experience motor control loss, speech/swallowing difficulties, respiratory insufficiency, and early death. Advancing disease stage is typically associated with a greater burden on the health care system, and delays in diagnosis can result in substantial health care resource utilization (HCRU).
Objective: To estimate HCRU and cost burden of plwALS across disease stages from a US payer perspective we assessed HCRU and costs in early-, mid-, and late-stage ALS.
Potential role of solid lipid curcumin particle (SLCP) as estrogen replacement therapy in mitigating TDP-43-related neuropathy in the mouse model of ALS disease.
Exp Neurol
January 2025
Ph.D. Program in Medical Neuroscience, College of Medical Science and Technology, Taipei Medical University and National Health Research Institutes, Taipei 110, Taiwan; International Master Program in Medical Neuroscience, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan; School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan; TMU Research Center of Neuroscience, Taipei Medical University, Taipei 110, Taiwan. Electronic address:
Article Synopsis
- The Ice Bucket Challenge in 2014 raised significant awareness about ALS, leading to research on treatments, but currently only three drugs exist that offer limited, temporary relief.
- There's a growing understanding that sex hormones, particularly 17β estradiol (E2), might play a crucial role in the onset and progression of ALS and FTLD, with studies showing E2 can benefit neurodegenerative diseases.
- This research investigates the role of TDP-43 and estrogen-related enzymes in ALS, exploring the potential of curcumin as a treatment by assessing its effects on E2 levels and TDP-43-related issues in an animal model.
Spinal cord injury in high-risk complex adult spinal deformity surgery: review of incidence and outcomes from the Scoli-RISK-1 study.
Spinal Cord Ser Cases
August 2024
Department of Surgery and Spine Program, University of Toronto, Toronto, ON, Canada.
Article Synopsis
- The study examines six cases of perioperative spinal cord injury (SCI) that occurred during complex adult deformity surgeries, noting their causes, treatments, and outcomes.
- Out of 272 patients from the Scoli-RISK-1 cohort study, 2.2% experienced SCI, with cases occurring both during and after surgery.
- The findings highlight the importance of close postoperative monitoring and timely intervention to prevent lasting neurological damage.
Pharmacological Treatment of Degenerative Cervical Myelopathy: A Critical Review of Current Evidence.
Neurospine
June 2024
Edinburgh Spinal Surgery Outcomes Study Group, Department of Neurosurgery, Royal Infirmary, Edinburgh, UK.
Article Synopsis
- Degenerative cervical myelopathy (DCM) is a major cause of spinal cord dysfunction in adults, leading to significant health issues and financial costs, with most patients requiring surgery eventually.
- The review examines various pharmacological agents that might help treat mild DCM or improve surgical results, highlighting mixed evidence for effectiveness in both human and animal studies.
- Key findings indicate that while some drugs like Riluzole and Cerebrolysin show potential in animal studies, their benefits in humans are inconclusive, and more robust clinical data is needed to explore new neuroprotective therapies for DCM.
Ebselen analogues delay disease onset and its course in fALS by on-target SOD-1 engagement.
Sci Rep
May 2024
Molecular Biophysics Group, Department of Biochemistry and System Biology, Institute of System, M0polecular and Integrative Biology, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, L69 7ZB, UK.
Amyotrophic lateral sclerosis (ALS) selectively affects motor neurons. SOD1 is the first causative gene to be identified for ALS and accounts for at least 20% of the familial (fALS) and up to 4% of sporadic (sALS) cases globally with some geographical variability. The destabilisation of the SOD1 dimer is a key driving force in fALS and sALS.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!